Tada A, Ogawa M, Inagaki J, Horikoshi N, Inoue K, Yamazaki H, Nakamura T, Ueno K, Mukaiyama T, Ito Y
Gan To Kagaku Ryoho. 1986 Jan;13(1):70-4.
Forty-nine patients with liver metastases of breast cancer were treated with arterial infusion involving simultaneous use of adriamycin: 30-50 mg and mitomycin C: 10-20 mg through the hepatic artery by Seldinger catheter. Of 45 evaluable patients, there were 5 complete and 12 partial responses (CR + PR: 38%), 21 no change and 7 cases of progressive disease. The median duration of response was 5 months. The median survival time was 7.5 months in all cases, 8.7 months for responders and 6.4 months for non-responders. Leukopenia less than 4 X 10(3)/mm3 was observed in 73% of cases, thrombocytopenia less than 100 X 10(3)/mm3 in 35%, and a decreased hemoglobin value of more than 2 g/dl in 4%, but these were well tolerated. Nausea (53%), vomiting (43%), fever (12%), abdominal pain (6%) and liver toxicity (2%) were observed, but these were manageable. We conclude that this arterial infusion therapy is a useful treatment modality for controlling liver metastases of breast cancer.
49例乳腺癌肝转移患者接受了动脉灌注治疗,通过Seldinger导管经肝动脉同时使用阿霉素30 - 50mg和丝裂霉素C 10 - 20mg。45例可评估患者中,5例完全缓解,12例部分缓解(完全缓解 + 部分缓解:38%),21例病情稳定,7例病情进展。缓解的中位持续时间为5个月。所有患者的中位生存时间为7.5个月,缓解者为8.7个月,未缓解者为6.4个月。73%的病例出现白细胞减少至低于4×10³/mm³,35%的病例出现血小板减少至低于100×10³/mm³,4%的病例血红蛋白值下降超过2g/dl,但这些均耐受性良好。观察到恶心(53%)、呕吐(43%)、发热(12%)、腹痛(6%)和肝毒性(2%),但这些均可控制。我们得出结论,这种动脉灌注治疗是控制乳腺癌肝转移的一种有效治疗方式。